For: | Liang J, Bai Y, Ha FS, Luo Y, Deng HT, Gao YT. Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(1): 1-18 [PMID: 36684055 DOI: 10.4251/wjgo.v15.i1.1] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v15/i1/1.htm |
Number | Citing Articles |
1 |
Changlong Hou, Baizhu Xiong, Lei Zhou, Yipeng Fei, Changgao Shi, Xianhai Zhu, Tao Xie, Yulin Wu. Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-12144-6
|
2 |
Beichuan Pang, Bangyou Zuo, Liang Huang, Xinyu You, Tao Liu, Jianjie Hao, Chengxiang Yuan, Chong Yang, Wan Yee Lau, Yu Zhang. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma. International Immunopharmacology 2024; 137: 112492 doi: 10.1016/j.intimp.2024.112492
|
3 |
Junning Liu, Guangnian Zhang, Linfeng Yang, Duan Yan, Jiahui Yu, Song Wei, Jijiang Li, Pengsheng Yi. Salvage liver transplantation versus curative treatment for patients with recurrent hepatocellular carcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology 2024; 50(7): 108427 doi: 10.1016/j.ejso.2024.108427
|